Carmell Corp - יחס שווי פעילות לרווח לפני ריבית, מסים ופחת XAGE

The current market quotes for Longevity Health Holdings (XAGE) visualized below, with an EV/EBITDA of , supplement data on a company with moderate macroeconomic resilience and a demand for aesthetic medicine that is moderately dependent on consumer income. The business minimizes risks by developing bioactive components for tissue regeneration in orthopedics. Sales of premium biotechnological products are currently scaling rapidly through specialized clinics.

This indicator determines the investment reliability of the issuer by comparing the total enterprise value, accounting for net debt and taxes, to its operating profit. Analyzing the current EV/EBITDA ratio with debt allows for the elimination of accounting distortions to assess the real value of assets. For Longevity Health Holdings (XAGE), such a metric confirms the stability of a capital-intensive pharmaceutical logistics infrastructure that ensures the integrity of medications during transport.